Estado de gracia, la serie dramática de ficción sobre el narcotráfico que aborda por primera vez el polémico tema de la legalización de las drogas en México, se estrena el lunes 4 de junio, en exclusiva a través de Cinelatino, el canal líder de películas en español en Estados Unidos. La serie que cuenta con altos estándares de producción no se ha visto en ningún otro país en el mundo.
Esta producción mexicana es un thriller de suspenso político que presenta un retrato realista sobre el fenómeno del narcotráfico en México, que arroja luz sobre la red de dinero, el poder y la corrupción que alimenta el negocio ilícito de las drogas.
Para más, va a http://www.multivu.com/mnr/56310-cinelatino-estado-de-gracia-mexico-drug-trade-legalization?lang=es
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Astellas Pharma Europe Ltd. today presented The Economist Innovation 2011 award for Bioscience to one of the world’s most influential biomedical engineers, Dr Robert Langer – the man responsible for founding the field of controlled-release drug delivery and tissue engineering.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellaspharma/52158/
Vikes, Dance Fever, French Fries. The names might not be familiar to you, but chances are good your kids have heard of them. These are the street names for prescription drugs, and more and more teens are using them to get high.
Each year, nearly 2 million teens abuse prescription drugs. The new parent’s Prescription and Over-the-Counter Drug Guide from BeSmartBeWell.com and The Partnership at Drugfree.org breaks down the most commonly abused prescription and over-the-counter drugs in a simple-to-understand and interactive web page. Learn drugs’ “street” names, how kids are using them (inject, inhale, etc.), why they're dangerous and the warning signs of abuse.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50821/
HealthCare Partners, a division of DaVita Inc. (NYSE: DVA), a leading independent medical group in the United States, is encouraging Medicare beneficiaries to review their health care coverage during Medicare’s Open Enrollment Period.
From October 15 through December 7, Medicare holds its annual Open Enrollment Period. During this seven-week window, Medicare beneficiaries can make changes to their health and prescription drug plans for the following year.
If you are satisfied with your Medicare coverage, you may wonder how open enrollment applies to you. As the old adage goes, “if it isn’t broke, don’t fix it,” right?
While this may certainly be the case for many things in life, it may not be true about your Medicare coverage. Choosing a Medicare plan is similar to shopping for other insurance; by comparing different plans and rates, you choose the coverage that’s best for you.
To view the multimedia release go to:
http://www.multivu.com/players/English/7920151-healthcare-partners-medicare-open-enrollment/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
As the rate of teen prescription drug abuse continues to rise in the United States, the National Association of School Nurses (NASN) and Janssen Pharmaceuticals, Inc., today joined with addiction expert Dr. Drew Pinsky,* to launch a new tool kit intended to help America’s schools educate teens and their parents about the risks and consequences of abusing prescription medication.
The Schools Get Smart, Schools Take Action Tool Kit is part of Smart Moves, Smart Choices, a national initiative of NASN and Janssen Pharmaceuticals, Inc., designed to inform parents, teens and educators about this growing problem of teen prescription drug abuse, and what they can do to combat it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/smartmovessmartchoices/51444/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
ILEX Consumer Products Group, a Baltimore-based company which owns and manages health and beauty as well as over the counter (OTC) drug brands, launched di-gel, a new antacid/anti-gas brand, just in time for all the overindulging and stress of the holidays.
The new digestive aid, which is being promoted with integrated TV and digital advertising, grassroots and public relations, launched with the brand tagline
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
